Michael P. Dillon - 09 Aug 2021 Form 4 Insider Report for IDEAYA Biosciences, Inc. (IDYA)

Role
SVP, Chief Scientific Officer
Signature
/s/ Jason Throne, as Attorney-in-Fact for Michael P. Dillon
Issuer symbol
IDYA
Transactions as of
09 Aug 2021
Net transactions value
-$257,804
Form type
4
Filing time
11 Aug 2021, 17:19:38 UTC
Previous filing
29 Jul 2021
Next filing
07 Sep 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IDYA Common Stock Options Exercise $6,465 +1,500 +1.5% $4.31* 100,289 09 Aug 2021 Direct
transaction IDYA Common Stock Sale $254,863 -11,100 -11% $22.96 89,189 09 Aug 2021 Direct F1, F2
transaction IDYA Common Stock Sale $9,406 -400 -0.45% $23.52 88,789 09 Aug 2021 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IDYA Stock Option (Right to Buy) Options Exercise $0 -1,500 -2.2% $0.000000 66,235 09 Aug 2021 Common Stock 1,500 $4.31 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.
F2 This transaction was executed in multiple trades in prices ranging from $22.48 to $23.46, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F3 This transaction was executed in multiple trades in prices ranging from $23.49 to $23.55, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F4 25% of the shares subject to the option vest on the first anniversary measured from February 27, 2018 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.